No CrossRef data available.
Published online by Cambridge University Press: 29 March 2005
Elizabeth H. Blackburn, Ph.D., is a leader in the area of telomere and telomerase research—in fact, in 1984 she codiscovered the ribonucleoprotein enzyme telomerase, opening up new potentials in cancer research and therapy. This and subsequent work has earned her numerous honors, not the least of which are the National Academy of Science Award in Molecular Biology, an Honorary Doctorate of Science from Yale University, the American Cancer Society Medal of Honor, and many more awards. Dr. Blackburn is a Fellow of the American Academy of Arts and Sciences, the Royal Society of London, the American Academy of Microbiology, and the American Association for the Advancement of Science. She was elected to the National Academy of Sciences, and is a Member of the Institute of Medicine.
Elizabeth H. Blackburn, Ph.D., is a leader in the area of telomere and telomerase research—in fact, in 1984 she codiscovered the ribonucleoprotein enzyme telomerase, opening up new potentials in cancer research and therapy. This and subsequent work has earned her numerous honors, not the least of which are the National Academy of Science Award in Molecular Biology, an Honorary Doctorate of Science from Yale University, the American Cancer Society Medal of Honor, and many more awards. Dr. Blackburn is a Fellow of the American Academy of Arts and Sciences, the Royal Society of London, the American Academy of Microbiology, and the American Association for the Advancement of Science. She was elected to the National Academy of Sciences, and is a Member of the Institute of Medicine.
A native Australian who did her graduate work at Yale, Blackburn joined the Department of Microbiology and Immunology at the University of California, San Francisco in 1990, where she is Morris Herzstein Professor of Biology and Physiology, and oversees a laboratory of 16 researchers. The Associated Press has called her a “scientific superstar.”
Clearly already renowned among her scientific and medical peers, early in 2004 Blackburn was thrust into the glare of media attention when she was removed from the President's Council of Bioethics. The controversy at hand was stem cell research, which Blackburn, as one of the few full-time scientists on that Council, supported as having true therapeutic potential for a variety of difficult diseases and conditions. Ironically, stem cell research is not her own area of research, but after being removed from the Council earlier this year, she became an outspoken advocate of this research, authoring fairly scathing editorials in medical journals (including one in the New England Journal of Medicine titled “Bioethics and the Political Distortion of Biomedical Science”) and in interviews in the general media.
Her own place in the controversy having settled down, we asked her to give us her story and perspectives on the stem cell issue.
Steve Heilig: To start, since you are such a leader in your field, is there anything you'd like to report regarding your own work?
Elizabeth Blackburn: We're trying to make telomerase kill cancer cells, and we are pretty excited these days, as telomerase does impact on cancer cells in ways we had not suspected. We thought it just made cells keep proliferating, but now we are finding that it is pushing cells in other cancer-promoting directions such as metastasis. Telomerase is thus more than an enzyme that just gives cells “permission” to multiply, but has an effect on the whole physiology of cancer cells. There thus is whole new potential for controlling such growth down the line.
SH: So stem cell research is not your own field, and even many physicians do not know very much about why this is important. Can you give your perspective on that?
EB: The importance of embryonic stem cells, which is the contended part of the discussion, is that in animal and now human studies it has been found that these cells have not only a very striking capacity to self-regenerate but also, under the right conditions, to form a whole variety of different cell types. This ability is related to the fact that they come from the very early stages of epigenesis when the embryo is just a blastocyst of 100–200 cells. The cells are able to self-renew and differentiate in culture and this suggests they have a lot of possibilities for regenerative medical applications. A couple of decades of animal research have shown this, and it is now seemingly true in human cells as well, where it has been possible to do some kind of regenerative medicine type of experiments to see what sort of capabilities there might be for treating humans.
SH: And what type of diseases or conditions might be most impacted?
EB: We can't give a “laundry list” yet as it is still too early to tell. The kinds of diseases are often very common ones like diabetes, and also less common ones like Parkinson's—which still affect a lot of people. Some of these diseases have been fairly intractable to medical science so it seems really important to see what we might do with human embryonic stem cells.
SH: There has been controversial Federal policy related to use of existing stem cell lines versus potential new ones. What does this debate mean in practice?
EB: I think the policy to limit the usable lines did not look very well at whether the number of existing cell lines—the number mentioned most often was 78—were actually usable. It turned out that the number was smaller, and that there were proprietary limits on some of those. So the reality was that the usable number is more like half a dozen to a dozen—which is a big problem as that is a very restrictive number for any kind of research with the broad-based kinds of goals such as we have with stem cell research.
SH: You were appointed by President Bush to the President's Council on Bioethics in late 2001. Was the restrictive policy a concern to you before then?
EB: Well, the President's Council was formed a few months after the restrictive policy and it had already become fairly clear among scientists what the real number of usable lines was—that it would be much less than 78, at least.
SH: Once the Council got to work, what kind of discussion on stem cell issues ensued—what were the primary ethical issues debated?
EB: Well, really the Council seemed immediately divided into those who felt there was an absolute moralist argument that the embryo should be treated as it were a full human being, versus another kind of thinking and view that even if there was some merit to that argument it had to be weighed against the moral right and needs of full human beings who could potentially benefit from such research.
SH: So it sounds like the debate was polarized and not very nuanced.
EB: Right—in a simplistic way the arguments broke down into sort of absolutist positions. If you say the embryo has a full right as a human being, that's end of the discussion for some.
SH: Did the chair of the Council, Leon Kass, make his own position clear?
EB: Oh yes—he really held to the view that the moral worth of the potential medical benefits of the research did not outweigh the arguments for the embryo's interest—that the blastocyst's 100–200 cells should not be violated.
SH: Were the Council's debates contentious?
EB: In the actual meetings, no—we were all adults and could discuss and say whatever we wanted to. Although I did sort of sense that the Chair would sometimes move the subject on from those who views he disagreed with, or expand on the discussion where he agreed with it. I think that's fair to say. The discussions were public by law, but behind the scenes there was a lot of dissension over the two years I was on the council.
SH: You've said you were dismayed, or at least surprised, with some of the reports that came out of the Council.
EB: Some of us, not just me, felt that the reports produced by the Chair after our deliberations did not always reflect the full input from the Council, and did not contain the full scientific perspectives we had provided.
SH: Did you voice this concern?
EB: For a while I had corresponded back and forth with the Chair, as did some others. We expressed our concerns but did not see much of a change in aspects in the reports that we thought ought to be more scientifically balanced.
SH: And then you were “replaced” on the Council—or as the Associated Press reported it, “fired by Bush.” Was this a surprise to you?
EB: I did not have any inkling of this until I heard from the White House Office of Presidential Personnel. This was surprising because not long before, the Chair said that the Council had been renewed for another two years, with no mention of any changes in membership.
SH: One of the media reports at the time quoted you as saying you did not feel martyred, but were in fact honored. Can you explain?
EB: Well, people were saying, “Oh, I'm so sorry you are off the Council, you must feel awful” and I'd say wait a minute, I have this extremely rewarding and busy full-time job and being on the Council was hardly my whole life—it was another committee with hard work. So I didn't feel bad in the sense of being fired from my job or something. It was community service with a tiny honorarium, the standard kind of thing physicians and scientists feel obligated and honored to do. One less committee was itself not a problem! But the “honored” part was because I felt that the principle of having balanced scientific research as the basis of reports coming from Federal sources was something I had “gone down defending,” if you will. And I still think that's a fairly important principle.
SH: After you were dismissed, over 170 researchers signed an open letter to President Bush in protest. And the American Society for Cell Biology, which represents 11,000 scientists worldwide, alleged that your treatment reflects a pattern of politics trumping science in the White House. Have you seen the reports from the Union of Concerned Scientists, Congress, and other sources that allege a pattern of White House interference with scientific integrity, and if so, do you think your experience fits with that pattern?
EB: I can't tell you I know the details of everyone else's experience, as I only know mine. But it certainly seems very similar in kind if not in specifics to what has happened to other scientists. The pattern seems very apparent to a great many people, and it really kind of struck a rather unpleasant chord with a lot of people when my particular case—which was not itself a huge deal—happened in a time where it got much more publicity than if it had been an isolated incident.
SH: Did all the publicity affect you or your work?
EB: Well, I'm used to some public attention in the scientific world. But yes, this was a different kind, and it seemed that people actually cared that science policy get made based on the best information. That was the theme of the innumerable e-mails, letters, and phone calls I received. That was very heartening as it seemed that people cared for the right reason.